ReviewDegenerative neurological and neuromuscular disease2013
The epidemiology and pathophysiology of pseudobulbar affect and its association with neurodegeneration.
Review in Degenerative neurological and neuromuscular disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Affect before diagnosis: applying affective neuroscience to psychiatry.Frontiers in psychiatry · 2026Article
- Pseudobulbar Affect: A Network Disorder Linking Emotion, Neurobiology, and Therapeutics.Cureus · 2025Review
- Pseudobulbar Affect Among Patients With Dementia.Cureus · 2025Article
- Suspected Pseudobulbar Affect in Neurodegenerative Disease.International journal of geriatric psychiatry · 2024Article
- Article
- Emotion Recognition in Multiple System Atrophy: An Exploratory Eye-Tracking Study.Journal of movement disorders · 2024Article
- Definitions, phenomenology, diagnosis, and management of the disorders of laughter and crying in amyotrophic lateral sclerosis (ALS): Consensus from ALS and Motor Neuron Disease Scientific Department of the Brazilian Academy of Neurology.Arquivos de neuro-psiquiatria · 2023Article
- Emotional Incontinence: A Case Report of Pseudobulbar Affect in the Setting of Alcohol Use Disorder.Cureus · 2023Article
- Thalamic pathology in frontotemporal dementia: Predilection for specific nuclei, phenotype-specific signatures, clinical correlates, and practical relevance.Brain and behavior · 2023Review
- Resting state fMRI analysis of pseudobulbar affect in Amyotrophic Lateral Sclerosis (ALS): motor dysfunction of emotional expression.Brain imaging and behavior · 2023Article
- Involuntary crying episodes with Susac's syndrome-a rare presentation of a rare disease: a case report.BMC neurology · 2022Article
- Article
- Survivorship Issues in Adult Patients With Histiocytic Neoplasms.Journal of the National Comprehensive Cancer Network : JNCCN · 2021Review
- A Unique Case of Valacyclovir Toxicity and Pseudobulbar Affect in a Patient On Peritoneal Dialysis.Cureus · 2021Article
- Brainstem Correlates of Pathological Laughter and Crying Frequency in ALS.Frontiers in neurology · 2021Article
- Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.JAMA internal medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudobulbar affect is a disorder resulting from neurologic damage manifesting as sudden, stereotyped affective outbursts that are not reflective of internal emotion. A literature review was completed to examine the current understanding of the epidemiology, characterization, diagnosis, pathophysiology, and treatment of pseudobulbar affect. This review revealed that it is common in neurodegenerative disorders but is poorly recognized, placing significant impacts on patients and their families. The disorder appears to result from a disruption of the cortico-limbic-subcortical-thalamic-pontocerebellar network involved in emotional expression and regulation with resulting disruptions of neurotransmitter systems. Effective treatment is available with agents such as selective serotonin reuptake inhibitors and dextromethorphan combined with quinidine, but further well-designed comparative studies are needed. Advances in technology such as neuroimaging may enhance knowledge about the pathophysiology of this disorder, and help guide future interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.